Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Evaluation of dosimetry, quantitative methods and test-retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain.

Bullich S, Barret O, Constantinescu C, Sandiego C, Mueller A, Berndt M, Papin C, Perrotin A, Koglin N, Kroth H, Pfeifer A, Tamagnan G, Madonia J, Seibyl JP, Marek K, de Santi S, Dinkelborg LM, Stephens AW.

J Nucl Med. 2019 Nov 11. pii: jnumed.119.236240. doi: 10.2967/jnumed.119.236240. [Epub ahead of print]

PMID:
31712324
2.

Tau PET imaging with 18F-PI-2620 in patients with Alzheimer's disease and healthy controls: a first-in-human study.

Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, Perrotin A, Koglin N, Kroth H, Pfeifer A, Tamagnan G, Seibyl JP, Marek K, de Santi S, Dinkelborg LM, Stephens AW.

J Nucl Med. 2019 Nov 11. pii: jnumed.119.236224. doi: 10.2967/jnumed.119.236224. [Epub ahead of print]

PMID:
31712323
3.

Radiation dosimetry of [18F]GP1 for imaging activated glycoprotein IIb/IIIa receptors with positron emission tomography in patients with acute thromboembolism.

Lee N, Oh I, Chae SY, Jin S, Oh SJ, Lee SJ, Koglin N, Berndt M, Stephens AW, Oh JS, Moon DH.

Nucl Med Biol. 2019 May - Jun;72-73:45-48. doi: 10.1016/j.nucmedbio.2019.07.003. Epub 2019 Jul 10.

PMID:
31330411
4.

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology.

Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S.

Alzheimers Dement. 2019 Jun;15(6):807-816. doi: 10.1016/j.jalz.2019.02.005. Epub 2019 May 14.

PMID:
31101517
5.

A phase 1, first-in-human study of 18F-GP1 positron emission tomography for imaging acute arterial thrombosis.

Chae SY, Kwon TW, Jin S, Kwon SU, Sung C, Oh SJ, Lee SJ, Oh JS, Han Y, Cho YP, Lee N, Kim JY, Koglin N, Berndt M, Stephens AW, Moon DH.

EJNMMI Res. 2019 Jan 7;9(1):3. doi: 10.1186/s13550-018-0471-8.

6.

Glycoprotein IIb/IIIa receptor imaging with 18F-GP1 positron emission tomography for acute venous thromboembolism: an open-label, non-randomized, first-in-human phase 1 study.

Kim C, Lee JS, Han Y, Chae SY, Jin S, Sung C, Son HJ, Oh SJ, Lee SJ, Oh JS, Cho YP, Kwon TW, Lee DH, Jang S, Kim B, Koglin N, Berndt M, Stephens AW, Moon DH.

J Nucl Med. 2018 Jun 29. pii: jnumed.118.212084. doi: 10.2967/jnumed.118.212084. [Epub ahead of print]

7.
8.

Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol.

Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, Stephens AW, Sabri O.

J Nucl Med. 2018 Jul;59(7):1104-1110. doi: 10.2967/jnumed.117.200964. Epub 2017 Nov 24.

9.

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059. doi: 10.1007/s00259-017-3749-6. Epub 2017 Jun 22.

10.

18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi.

Lohrke J, Siebeneicher H, Berger M, Reinhardt M, Berndt M, Mueller A, Zerna M, Koglin N, Oden F, Bauser M, Friebe M, Dinkelborg LM, Huetter J, Stephens AW.

J Nucl Med. 2017 Jul;58(7):1094-1099. doi: 10.2967/jnumed.116.188896. Epub 2017 Mar 16.

11.

New protein deposition tracers in the pipeline.

Jovalekic A, Koglin N, Mueller A, Stephens AW.

EJNMMI Radiopharm Chem. 2017;1(1):11. doi: 10.1186/s41181-016-0015-3. Epub 2016 Jun 2. Review. Erratum in: EJNMMI Radiopharm Chem. 2018 Nov 26;3:13.

12.

Utility of [18F]FSPG PET to Image Hepatocellular Carcinoma: First Clinical Evaluation in a US Population.

Kavanaugh G, Williams J, Morris AS, Nickels ML, Walker R, Koglin N, Stephens AW, Washington MK, Geevarghese SK, Liu Q, Ayers D, Shyr Y, Manning HC.

Mol Imaging Biol. 2016 Dec;18(6):924-934.

13.

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.

Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, Iagaru AH, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS.

PLoS One. 2016 Feb 18;11(2):e0148628. doi: 10.1371/journal.pone.0148628. eCollection 2016.

14.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.

15.

Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study.

Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Takao M, Akatsu H, Murayama S, Bullich S, Mueller A, Koglin N, Schulz-Schaeffer WJ, Hoffmann A, Sabbagh MN, Stephens AW, Sabri O.

J Nucl Med. 2016 Jun;57(6):900-6. doi: 10.2967/jnumed.115.161927. Epub 2016 Jan 28.

16.

Characterization of Physiologic (18)F FSPG Uptake in Healthy Volunteers.

Mosci C, Kumar M, Smolarz K, Koglin N, Stephens AW, Schwaiger M, Gambhir SS, Mittra ES.

Radiology. 2016 Jun;279(3):898-905. doi: 10.1148/radiol.2015142000. Epub 2016 Jan 18.

PMID:
26785040
17.

Exploratory Clinical Investigation of (4S)-4-(3-18F-Fluoropropyl)-L-Glutamate PET of Inflammatory and Infectious Lesions.

Chae SY, Choi CM, Shim TS, Park Y, Park CS, Lee HS, Lee SJ, Oh SJ, Kim SY, Baek S, Koglin N, Stephens AW, Dinkelborg LM, Moon DH.

J Nucl Med. 2016 Jan;57(1):67-9. doi: 10.2967/jnumed.115.164020. Epub 2015 Oct 15.

18.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group.

Alzheimers Dement. 2015 Aug;11(8):964-74. doi: 10.1016/j.jalz.2015.02.004. Epub 2015 Mar 28.

19.

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD.

Lancet Oncol. 2015 Apr;16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18.

20.

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.

Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP.

Clin Cancer Res. 2015 Feb 15;21(4):693-700. doi: 10.1158/1078-0432.CCR-14-0265. Epub 2014 Sep 10.

21.

Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.

Ong KT, Villemagne VL, Bahar-Fuchs A, Lamb F, Langdon N, Catafau AM, Stephens AW, Seibyl J, Dinkelborg LM, Reininger CB, Putz B, Rohde B, Masters CL, Rowe CC.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):431-6. doi: 10.1136/jnnp-2014-308094. Epub 2014 Jun 26.

PMID:
24970906
22.

Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.

Koglin N, Mueller A, Berndt M, Schmitt-Willich H, Toschi L, Stephens AW, Gekeler V, Friebe M, Dinkelborg LM.

Clin Cancer Res. 2011 Sep 15;17(18):6000-11. doi: 10.1158/1078-0432.CCR-11-0687. Epub 2011 Jul 12.

23.

A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.

Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ Sr.

Am J Clin Oncol. 2011 Oct;34(5):460-5. doi: 10.1097/COC.0b013e3181e9c103.

PMID:
20881474
24.

A gamma-ray burst at a redshift of z approximately 8.2.

Tanvir NR, Fox DB, Levan AJ, Berger E, Wiersema K, Fynbo JP, Cucchiara A, Krühler T, Gehrels N, Bloom JS, Greiner J, Evans PA, Rol E, Olivares F, Hjorth J, Jakobsson P, Farihi J, Willingale R, Starling RL, Cenko SB, Perley D, Maund JR, Duke J, Wijers RA, Adamson AJ, Allan A, Bremer MN, Burrows DN, Castro-Tirado AJ, Cavanagh B, de Ugarte Postigo A, Dopita MA, Fatkhullin TA, Fruchter AS, Foley RJ, Gorosabel J, Kennea J, Kerr T, Klose S, Krimm HA, Komarova VN, Kulkarni SR, Moskvitin AS, Mundell CG, Naylor T, Page K, Penprase BE, Perri M, Podsiadlowski P, Roth K, Rutledge RE, Sakamoto T, Schady P, Schmidt BP, Soderberg AM, Sollerman J, Stephens AW, Stratta G, Ukwatta TN, Watson D, Westra E, Wold T, Wolf C.

Nature. 2009 Oct 29;461(7268):1254-7. doi: 10.1038/nature08459.

PMID:
19865165
25.

Tumor targeting by an aptamer.

Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG.

J Nucl Med. 2006 Apr;47(4):668-78.

26.

Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.

Schmidt KS, Borkowski S, Kurreck J, Stephens AW, Bald R, Hecht M, Friebe M, Dinkelborg L, Erdmann VA.

Nucleic Acids Res. 2004 Oct 27;32(19):5757-65. Print 2004.

27.

Probing hydrogen-bonding interactions in the active site of medium-chain acyl-CoA dehydrogenase using Raman spectroscopy.

Wu J, Bell AF, Luo L, Stephens AW, Stankovich MT, Tonge PJ.

Biochemistry. 2003 Oct 14;42(40):11846-56.

PMID:
14529297
28.

Medium-chain acyl-coenzyme A dehydrogenase bound to a product analogue, hexadienoyl-coenzyme A: effects on reduction potential, pK(a), and polarization.

Pellett JD, Sabaj KM, Stephens AW, Bell AF, Wu J, Tonge PJ, Stankovich MT.

Biochemistry. 2000 Nov 14;39(45):13982-92.

PMID:
11076541
29.

Escort aptamers: a delivery service for diagnosis and therapy.

Hicke BJ, Stephens AW.

J Clin Invest. 2000 Oct;106(8):923-8. No abstract available.

30.

Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.

Stephens AW, Gonin R, Hutchins GD, Einhorn LH.

J Clin Oncol. 1996 May;14(5):1637-41.

PMID:
8622082
32.

High-affinity RNA ligands to human alpha-thrombin.

Kubik MF, Stephens AW, Schneider D, Marlar RA, Tasset D.

Nucleic Acids Res. 1994 Jul 11;22(13):2619-26.

33.

A case of disseminated intravascular coagulation.

Stephens AW.

J Tenn Med Assoc. 1992 Jul;85(7):330, 332. No abstract available.

PMID:
1320712
34.

Site-directed mutagenesis of the reactive center (serine 394) of antithrombin III.

Stephens AW, Siddiqui A, Hirs CH.

J Biol Chem. 1988 Nov 5;263(31):15849-52.

35.

Expression of functionally active human antithrombin III.

Stephens AW, Siddiqui A, Hirs CH.

Proc Natl Acad Sci U S A. 1987 Jun;84(11):3886-90.

36.

Antithrombin-III Denver, a reactive site variant.

Stephens AW, Thalley BS, Hirs CH.

J Biol Chem. 1987 Jan 25;262(3):1044-8.

37.

Sequence variation in heparin octasaccharides with high affinity for antithrombin III.

Atha DH, Stephens AW, Rimon A, Rosenberg RD.

Biochemistry. 1984 Nov 20;23(24):5801-12.

PMID:
6525337
38.

Evaluation of critical groups required for the binding of heparin to antithrombin.

Atha DH, Stephens AW, Rosenberg RD.

Proc Natl Acad Sci U S A. 1984 Feb;81(4):1030-4.

39.

Non-specific complement fixation with Coxiella burnetii and psittacosis antigens in adenovirus pneumonia.

Stephens AW.

Med Lab Technol. 1971 Apr;28(2):205-7. No abstract available.

PMID:
4326696

Supplemental Content

Loading ...
Support Center